drugset / Trial / NCT06004986
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Phase 4
Recruiting
216 enrolled
Academic Medical Center - University of Amsterdam
Erasmus Medical Center · collabProthya Biosolutions · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.
Timeline
- Start
- 2023-08-14
- Primary completion
- 2025-10-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |